FSD Pharma Inc.

Equities

HUGE

CA35954B4047

Biotechnology & Medical Research

Delayed Canadian Securities Exchange 10:44:21 2024-04-24 am EDT 5-day change 1st Jan Change
0.64 CAD 0.00% Intraday chart for FSD Pharma Inc. 0.00% -46.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
FSD Pharma Receives Nasdaq Non-Compliance Notice MT
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO MT
FSD Pharma Brief: Signed Agreement With iNGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults MT
FSD Pharma Brief: Submitting a Phase-1b Clinical Trial Application for its Proprietary Beverage unbuzzd MT
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd CI
FSD Pharma Presents "Positive" Phase 1 Lucid-21-302 Results at ACTRIMS Forum MT
Refile-- FSD Pharma Brief: Presenting "Positive" Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum MT
FSD Pharma Brief: Presenting "Positive: Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum MT
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum CI
MT Newswires Canada Stocks To Watch: SSR Mining, Tricon Residential; Imperial Oil; FSD Pharma MT
Reflile: FSD Pharma Up 3.7% In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million MT
FSD Pharma Up 3.7$ In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million MT
FSD Pharma Brief: Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million MT
FSD Pharma Inc. Announces Board Changes CI
FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus MT
FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding CI
FSD Pharma Inc. completed the Spin-Off of Celly Nutrition Corp. CI
FSD Pharma Inc. announced that it expects to receive CAD 0.000046 million in funding CI
FSD Pharma Inc. Announces Change of CEO CI
FSD Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
FSD Pharma Enters Agreement on Distribution of Portion of Celly Nutrition Shareholdings MT
FSD Pharma Inc. agreed to Spin-Off 34.66% stake of Celly Nutrition Corp. CI
FSD Pharma Shares Rise After Saying Interim Report Shows Multiple Sclerosis Treatment Candidate Safe, Well-Tolerated MT
FSD Pharma Announces Interim Results from First-In-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis CI
Chart FSD Pharma Inc.
More charts
FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.
More about the company
  1. Stock Market
  2. Equities
  3. HUGE Stock
  4. News FSD Pharma Inc.
  5. FSD Pharma Subsidiary, Lucid Psycheceuticals, Files for Patent on Palmitoylethanolamide Formulations